Search by Drug Name or NDC

    NDC 53808-1120-01 Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 5; 12.5; 20 mg/1; mg/1; mg/1 Details

    Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 5; 12.5; 20 mg/1; mg/1; mg/1

    Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by DOH CENTRAL PHARMACY. The primary component is AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL.

    Product Information

    NDC 53808-1120
    Product ID 53808-1120_7c89cbae-fd36-4723-b4df-e0d71f786070
    Associated GPIs
    GCN Sequence Number n/a
    GCN Sequence Number Description n/a
    HIC3 n/a
    HIC3 Description n/a
    GCN n/a
    HICL Sequence Number n/a
    HICL Sequence Number Description n/a
    Brand/Generic n/a
    Proprietary Name Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide
    Proprietary Name Suffix n/a
    Non-Proprietary Name olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form TABLET, FILM COATED
    Route ORAL
    Active Ingredient Strength 5; 12.5; 20
    Active Ingredient Units mg/1; mg/1; mg/1
    Substance Name AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
    Labeler Name DOH CENTRAL PHARMACY
    Pharmaceutical Class Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Calcium Channel Antagonists [MoA], Dihydropyridine Calcium Channel Blocker [EPC], Dihydropyridines [CS], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA200175
    Listing Certified Through 2023-12-31

    Package

    NDC 53808-1120-01 (53808112001)

    NDC Package Code 53808-1120-1
    Billing NDC 53808112001
    Package 30 TABLET, FILM COATED in 1 BLISTER PACK (53808-1120-1)
    Marketing Start Date 2018-10-25
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 852df50b-14bb-408f-b9c2-2cb708d24d76 Details

    Revised: 1/2019